Want to see NAMS full AI Analyst Report?
NAMS Stock Chart & Stats
$26.79
$0.58(1.96%)
At close: 4:00 PM EDT
$26.79
$0.58(1.96%)
Day’s Range― - ―
52-Week Range$21.23 - $42.21
Previous Close$30.22
Volume948.74K
Average Volume (3M)1.25M
Market Cap
$2.73B
Enterprise Value$3.55K
Total Cash (Recent Filing)$633.85M
Total Debt (Recent Filing)$82.00K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 11, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding119,537,170
10 Day Avg. Volume1,497,666
30 Day Avg. Volume1,254,966
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$53.29Price Target Upside98.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.89
Revenue Forecast (FY)$30.26M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetMinimal debt and substantial equity provide a meaningful capital cushion for continued clinical development. This reduces near-term financial fragility, preserves funding flexibility, and gives NewAmsterdam more capacity to absorb operating volatility while advancing its pipeline.
European Regulatory ProgressThe positive CHMP opinion materially de-risks obicetrapib’s European development path. Menarini’s commercialization role, tiered double-digit royalties, and up to €833 million of potential milestones create a scalable future monetization route if final approval is granted.
Experienced Financial LeadershipGunning’s appointment adds experienced financial leadership from multiple biotechnology companies. Stronger accounting oversight supports governance, reporting quality, and financial controls as NewAmsterdam operates through a regulated and capital-intensive development stage.
Bears Say
Large Operating LossesThe sharp revenue decline and very large net loss show that current operations have not converted development investment into sustainable earnings. The wide gap between revenue and costs may remain until obicetrapib or another candidate is approved and commercialized.
Persistent Cash BurnHeavy operating and free-cash-flow burn indicates reliance on external funding rather than internally generated cash. Continued losses can reduce the company’s capital cushion over time and increase the importance of financing, partnerships, or future product receipts.
Approval-Dependent Revenue ModelNewAmsterdam remains dependent on successful development, regulatory approval, and commercialization to establish durable operating revenue. Until those milestones occur, collaboration receipts and financing activities remain important to sustaining the business and funding its pipeline.
NewAmsterdam Pharma Company News
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $21.23 and its highest was $42.20 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $2.73B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Nov 11, 2026 which is in 57 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Aug 05, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.482 by -$0.038.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.5.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 119,537,170 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.482. Following the earnings report the stock price went down -0.472%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.29 (98.90% Upside)
$53.29 (98.90% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 67%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$53.29
▲(98.90% Upside)
Technical Analysis
Ownership Overview
6.04% Insiders
21.96% Mutual Funds
19.36% Other Institutional Investors
50.81% Public Companies and
Individual Investors